Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Recruiting 7Active not recruiting 6Terminated 5Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 3Cyclophosphamide 3zanubrutinib 2fludarabine 2tafasitamab 1resiniferatoxin 1obinutuzumab 1duvelisib 1Vincristine 1Vancomycin 1Thiotepa 1Surveys and Questionnaires 1Radiotherapy 1Prednisone 1Prednisolone 1PTH2 protein, human 1Observation 1Neuropsychological Tests 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Interleukin-2 1Injections, Subcutaneous 1Homoharringtonine 1Glucocorticoids 1Doxorubicin 1Dexamethasone 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Non-Hodgkin × obinutuzumab × Clear all
NCT06427213 2024-05-23

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Henan Cancer Hospital

Phase 2 Not yet recruiting
41 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡